Literature DB >> 274738

Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line.

T Boon, A Van Pel.   

Abstract

We reported previously that, by mutagenesis of a malignant teratocarcinoma cell line, it is possible to obtain a number of variant clones that are incapable of forming progressive tumors. Each of these "tum-" variants is rejected in syngeneic mice and stimulates the production of immune memory cells (self-protection). We show here that four different tum- clones confer an immune protection against each other although this cross-protection is invariably weaker than the self-protection. Moreover, mice immunized with living tum- cells are partially protected against the original malignant teratocarcinoma cells, even though the latter cells are incapable of conferring any immune protection when injected after being killed by irradiation. These results indicate that each tum- variant carries at least one specific transplantation antigen that is absent from the original tumor cell line and from most other tum- variants. Other tumor-specific transplantation antigens are probably present on all the tum- variants and also on the malignant teratocarcinoma cell line.

Entities:  

Mesh:

Year:  1978        PMID: 274738      PMCID: PMC411504          DOI: 10.1073/pnas.75.3.1519

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  16 in total

1.  DIFFERENTIAL RADIOSENSITIVITY OF FIRST AND SECOND-SET RESPONSES TO ALLOGENEIC AND XENOGENEIC SKIN GRAFTS IN SUBLETHALLY IRRADIATED MICE.

Authors:  M L TYAN; L J COLE
Journal:  Transplantation       Date:  1963-10       Impact factor: 4.939

2.  Fate of skin homografts in x-irradiated mice treated with homologous marrow.

Authors:  J M MAIN; R T PREHN
Journal:  J Natl Cancer Inst       Date:  1957-12       Impact factor: 13.506

3.  Prolongation of survival of skin homotransplants in the rabbit by irradiation of the host.

Authors:  W J DEMPSTER; B LENNOX; J W BOAG
Journal:  Br J Exp Pathol       Date:  1950-10

Review 4.  Tumor progression and homeostasis.

Authors:  R T Prehn
Journal:  Adv Cancer Res       Date:  1976       Impact factor: 6.242

5.  [Teratocarcinoma of the mouse: isolation, culture and properties of pluripotential cells].

Authors:  H Jakob; T Boon; J Gaillard; J Nicolas; F Jacob
Journal:  Ann Microbiol (Paris)       Date:  1973-10

6.  Letter: Absence of serologically detectable H-2 on primitive teratocarcinoma cells in culture.

Authors:  K Artzt; F Jacob
Journal:  Transplantation       Date:  1974-06       Impact factor: 4.939

7.  Neoplastic differentiation: characteristics of cell lines derived from a murine teratocarcinoma.

Authors:  J M Lehman; W C Speers; D E Swartzendruber; G B Pierce
Journal:  J Cell Physiol       Date:  1974-08       Impact factor: 6.384

Review 8.  Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution.

Authors:  G Klein; E Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

9.  Surface antigens common to mouse cleavage embryos and primitive teratocarcinoma cells in culture.

Authors:  K Artzt; P Dubois; D Bennett; H Condamine; C Babinet; F Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1973-10       Impact factor: 11.205

10.  Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line.

Authors:  T Boon; O Kellermann
Journal:  Proc Natl Acad Sci U S A       Date:  1977-01       Impact factor: 11.205

View more
  24 in total

Review 1.  Immune recognition of self in immunity against cancer.

Authors:  Alan N Houghton; José A Guevara-Patiño
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 2.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

3.  A 6-thioguanine-resistant variant of the rat mammary adenocarcinoma 13762 that is more immunogenic.

Authors:  D S Hoon; I A Ramshaw
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

4.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice.

Authors:  C Uyttenhove; J Van Snick; T Boon
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

5.  Immunologic studies of membrane mutants of a highly metastatic murine tumor.

Authors:  R S Kerbel
Journal:  Am J Pathol       Date:  1979-12       Impact factor: 4.307

6.  NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.

Authors:  Paul Spear; Amorette Barber; Agnieszka Rynda-Apple; Charles L Sentman
Journal:  Immunol Cell Biol       Date:  2013-04-30       Impact factor: 5.126

7.  Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngeneic mice.

Authors:  A Van Pel; M Georlette; T Boon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

Review 8.  Immunology of metastasis. Can the immune response cope with disseminated tumor?

Authors:  P Frost; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

9.  Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis.

Authors:  A Van Pel; T Boon
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

Review 10.  Tumor progression in metastasis: an experimental approach using lectin resistant tumor variants.

Authors:  R S Kerbel; J W Dennis; A E Largarde; P Frost
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.